TNF-α -308G>A and IL-6 -174G>C polymorphisms in Tunisian patients with coronary artery disease

Clinical Biochemistry

Volumn 43, Issue 13-14, 2010, Pages 1085-1089

  Ghazouani, Lakhdar ^a   Hadj Khalifa, Sonia Ben ^a   Abboud, Nesrine ^a   Hamda, Khaldoun Ben ^b   Khalfallah, Ali Ben ^c   Brahim, Nsiri ^a   Almawi, Wassim Youssef ^d   Mahjoub, Touhami ^a  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b FATTOUMA BOURGUIBA UNIVERSITY HOSPITAL   (Tunisia)

^c Hopital Menzel Bourguiba   (Tunisia)

^d ARABIAN GULF UNIVERSITY   (Bahrain)

Author keywords

Coronary artery disease; Inflammatory cytokine; Interleukin 6; Polymorphisms; TNF

Indexed keywords

GENOMIC DNA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; IMMUNE SYSTEM; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TUNISIA;

ADULT; AGED; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; TUMOR NECROSIS FACTOR-ALPHA; TUNISIA;

EID: 77956176283     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2010.05.005     Document Type: Article

References (43)

1. Rosamond W., Flegal K., Furie K., et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008, 117:25-146.
2. Thim T., Hagensen M.K., Bentzon J.F., et al. From vulnerable plaque to atherothrombosis. J Intern Med 2008, 263:506-516.
3. Fernandez-Real J.M., Ricart W. Insulin resistance and inflammation in an evolutionary perspective. The contribution of cytokine genotype/phenotype to thriftiness. Diabetologia 1999, 42:1367-1374.
4. Dzielak D.J. The immune system and hypertension. Hypertension 1992, 19:136-144.
5. Zinman B., Hanley A.J.G., Harris S.B., et al. Circulating tumor necrosis factor-α concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. J Clin Endocrinol Metab 1999, 84:2172-2178.
6. Fernandez-Real J.M., Gutierrez C., Ricart W., et al. Plasma levels of the soluble fraction of tumor necrosis factor-a receptors 1 and 2 are independent determinants of total and LDL-cholesterol concentrations in healthy subjects. Atherosclerosis 1999, 146:321-327.
7. Winkler G., Lakatos P., Salamon F., et al. Elevated serum TNF-a levels as a link between endothelial dysfunction and insulin resistance in normotensive obese subjects. Diabet Med 1999, 16:207-211.
8. Fernandez-Real J.M., Broch M., Ricart W., et al. Plasma levels of the soluble fraction of tumor necrosis factor receptor-2 and insulin resistance. Diabetes 1998, 47:1757-1762.
9. Libby P. Changing concepts of atherogenesis. J Intern Med 2000, 247:349-358.
10. Inoue T., Uchida T., Yaguchi I., et al. Stent-induced expression and activation of the leukocyte integrin Mac-1 is associated with neointimal thickening and restenosis. Circulation 2003, 107:1757-1763.
11. Hansson G.K. Cell-mediated immunity in atherosclerosis. Curr Opin Lipidol 1997, 8:301-311.
12. Stephan F., Christopher H., Andreas M.Z. Inflammatory markers and coronary artery disease. Curr Opin Pharmacol 2004, 4:124-131.
13. Ridker P.M., Rifai N., Stampfer M.J., et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000, 101:1767-1772.
14. Hojo Y., Ikeda U., Takahashi M., et al. Increased levels of monocyte-related cytokines in patients with unstable angina. Atherosclerosis 2002, 161:403-408.
15. Plutzky J. Inflammatory pathways in atherosclerosis and acute coronary syndromes. Am J Cardiol 2001, 88:10-15.
16. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation 2002, 105:1135-1143.
17. Zakynthinos E., Pappa N. Inflammatory biomarkers in coronary artery disease. J Cardiol 2009, 53:317-333.
18. Fishman D., Faulds G., Jeffery R., et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998, 102:1369-1376.
19. Wilson A.G., Symons J.A., McDowell T.L., et al. Effects of a polymorphism in the human tumor necrosis factor a promoter on transcriptional activation. Proc Natl Acad Sci USA 1997, 94:3195-3199.
20. Report of the Joint International Society, Federation of Cardiology/World Health Organization Task Force on standardization of clinical nomenclature and criteria for diagnosis of ischemic heart disease. Circulation 1979, 59:607-608.
21. Pascual M., Nieto A., Matarán L., et al. IL-6 promoter polymorphisms in rheumatoid arthritis. Genes Immun 2000, 1:338-340.
22. Drakopoulou M., Toutouzas K., Stefanadi E., et al. Association of inflammatory markers with angiographic severity and extent of coronary artery disease. Atherosclerosis 2009, 206:335-339.
23. Anna A.R., Suzan A.R. Inflammation: a pivotal link between autoimmune diseases and atherosclerosis. Autoimmun Rev 2006, 5:331-337.
24. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005, 352:1685-1695.
25. Szodoray P., Timar O., Veres K., et al. TH1/TH2 imbalance, measured by circulating and intracytoplasmic inflammatory cytokines-immunological alterations in acute coronary syndrome and stable coronary artery disease. Scand J Immunol 2006, 64:336-344.
26. Banerjee I., Pandey U., Hasan O.M., et al. Association between inflammatory gene polymorphisms and coronary artery disease in an Indian population. J Thromb Thrombolysis 2009, 27:88-94.
27. Kelberman D., Hawe E., Luong L.A., et al. HIFMECH Study Group. HIFMECH Study Group, effect of interleukin-6 promoter polymorphisms in survivors of myocardial infarction and matched controls in the North and South of Europe. The HIFMECH Study. Thromb Haemost 2004, 92:1122-1128.
28. Sekuri C., Cam F.S., Sagcan A., et al. No association of interleukin-6 gene polymorphism (-174 G/C) with premature coronary artery disease in a Turkish cohort. Coron Artery Dis 2007, 18:333-337.
29. Burzotta F., Iacoviello L., Di Castelnuovo A., et al. Relation of the -174 G/C polymorphism of interleukin-6 to interleukin-6 plasma levels and to length of hospitalization after surgical coronary revascularization. Am J Cardiol 2001, 88:1125-1128.
30. Yamada Y., Izawa H., Ichihara S., et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med 2002, 347:1916-1923.
31. Nauck M., Winkelmann B.R., Hoffmann M.M., et al. The interleukin-6 G(-174)C promoter polymorphism in the LURIC cohort: no association with plasma interleukin-6, coronary artery disease, and myocardial infarction. Mol Med 2002, 80:507-513.
32. Bennermo M., Held C., Green F., et al. Prognostic value of plasma interleukin-6 concentrations and the -174 G>C and -572 G>C promoter polymorphisms of the interleukin-6 gene in patients with acute myocardial infarction treated with thrombolysis. Atherosclerosis 2004, 174:157-163.
33. Latkovskis G., Licis N., Kalnins U. C-reactive protein levels and common polymorphisms of the interleukin-1 gene cluster and interleukin-6 gene in patients with coronary heart disease. Eur J Immunogenet 2004, 31:207-213.
34. Lieb W., Pavlik R., Erdmann J., et al. No association of interleukin-6 gene. Polymorphism (-174 G/C) with myocardial infarction or traditional cardiovascular risk factors. Int J Cardiol 2004, 97:205-212.
35. Woods A., Brull D.J., Humphries S.E., et al. Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. Eur Heart J 2000, 21:1574-1583.
36. Lindmark E., Diderholm E., Wallentin L., et al. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or non invasive strategy. JAMA 2001, 286:2107-2113.
37. Licastro F., Chiappelli M., Caldarera C.M., et al. The concomitant presence of polymorphic alleles of interleukin-1beta, interleukin-6 and apolipoprotein E is associated with an increased risk of myocardial infarction in elderly men. Results from a pilot study. Mech Ageing Dev 2004, 125:575-579.
38. Reiner A.P., Diehr P., Browner W.S., et al. Common promoter polymorphisms of inflammation and thrombosis genes and longevity in older adults: the cardiovascular health study. Atherosclerosis 2005, 181:175-183.
39. Francis S.E., Camp N.J., Dewberry R.M., et al. Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease. Circulation 1999, 99:861-866.
40. Koch W., Tiroch K., von Beckerath N., et al. Tumor necrosis factor-alpha, lymphotoxin-alpha, and interleukin-10 gene polymorphisms and restenosis after coronary artery stenting. Cytokine 2003, 24:161-171.
41. Bernard V., Pillois X., Dubus I., et al. The -308G/A tumor necrosis factor-alpha gene dimorphism: a risk factor for unstable angina. Clin Chem Lab Med 2003, 41:511-516.
42. Antonicelli R., Olivieri F., Cavallone L., et al. Tumor necrosis factor-alpha gene -308G>A polymorphism is associated with ST-elevation myocardial infarction and with high plasma levels of biochemical ischemia markers. Coron Artery Dis 2005, 16:489-493.
43. Vendrell J., Fernandez-Real J.M., Gutierrez C., et al. A polymorphism in the promoter of the tumor necrosis factor-α gene (-308) is associated with coronary heart disease in type 2 diabetic patients. Atherosclerosis 2003, 167:257-264.